DALLAS and FORT WORTH, Texas, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late-stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the Stifel 2015 Healthcare Conference on November 18, 2015 at 3:00 p.m. ET in New York. Dr. Garg will provide a corporate update and discuss the company’s key milestones and events since their initial public offering.
A live webcast of the presentation will be available on the investor section of the company’s website, http://investors.neostx.com/. The webcast will be archived on the website following the presentation.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on the treatment of ADHD and has developed three branded product candidates that are XR medications in patient-friendly ODT or liquid suspension dosage forms. In addition, Neos Therapeutics manufactures and markets its generic equivalent of the branded product Tussionex, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
CONTACT: Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics (972) 408-1389 reisenstadt@neostx.com David Carey, Investor Relations Lazar Partners (212) 867-1768 dcarey@lazarpartners.com
Help employers find you! Check out all the jobs and post your resume.
